Stiris Research Inc. Announces Collaboration With US Biotech Company On Their Neurological Movement Disorder Trial

Cambridge, MA — November 6, 2019 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it has been awarded a Phase II neurological movement disorder trial.

“All of us at Stiris are excited to embark on this rare movement disorder trial. Our highly experienced team is looking forward to working on this novel therapy and getting new treatments into patients suffering from these degenerative disorders. Stiris’ “why” is to collaborate in life sciences to improve the lives of others, and this is exactly the type of work we are passionate about, and it allows us to continue to achieve our why” said Amanda Carrera, Vice President.

Movement is an intricate communication between the central nervous system, nerves and muscles. The basal ganglia guide voluntary muscle movements and suppresses involuntary movements. Where the cerebellum is responsible for coordination allowing smooth and accurate movement. Movement disorders affect day-to-day lives, ranging in severity. They include a lack of coordination, involuntary movements and tremors. Each of which targets different muscle groups including visual and speaking abilities. Treatment for such disorders tends to overlap with well-known disorders. Focused research on rare movement disorders is necessary for targeted, more effective treatment options.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.